OMEROS CORP Long-term Debt, Gross
OMEROS CORP (OMER) had Long-term Debt, Gross of $68.43 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentCarryingAmount · last filed 2026-03-31
- 2025-12-31: Long-term Debt, Gross $68.43M.
- 2025-09-30: Long-term Debt, Gross $176.59M.
- 2025-06-30: Long-term Debt, Gross $167.80M.
- 2025-03-31: Long-term Debt, Gross $185.89M.
| Period end | Long-term Debt, Gross |
|---|---|
| 2025-12-31 | $68.43M 10-K · filed 2026-03-31 |
| 2025-09-30 | $176.59M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $167.80M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $185.89M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $187.58M 10-K · filed 2025-03-31 |
| 2024-09-30 | $189.46M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $191.39M 10-Q · filed 2024-08-07 |
| 2023-12-31 | $215.92M 10-K · filed 2024-04-01 |
| 2023-09-30 | $320.03M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $320.03M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $320.03M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $320.03M 10-K · filed 2024-04-01 |
| 2022-09-30 | $320.03M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $320.03M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $320.03M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $320.03M 10-K · filed 2023-03-13 |
| 2021-09-30 | $320.03M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $320.03M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $320.03M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $320.03M 10-K · filed 2022-03-01 |
| 2020-09-30 | $320.03M 10-Q · filed 2020-11-09 |
| 2019-12-31 | $210.00M 10-Q · filed 2020-11-09 |
| 2013-09-30 | $20.00M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $20.00M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $20.00M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $20.00M 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |